{
    "Trade/Device Name(s)": [
        "Lumipulse G B\u2022R\u2022A\u2022H\u2022M\u2022S PCT Immunoreaction Cartridges",
        "Lumipulse G B\u2022R\u2022A\u2022H\u2022M\u2022S PCT Calibrators set"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K172713",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "NTM",
        "PMT"
    ],
    "Summary Letter Date": "September 7, 2017",
    "Summary Letter Received Date": "September 8, 2017",
    "Submission Date": "December 6, 2017",
    "Regulation Number(s)": [
        "21CFR866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sodium heparin tube",
        "Lithium heparin tube",
        "Sodium citrate tube",
        "Dipotassium EDTA tube",
        "SST",
        "K2EDTA tube",
        "Red top serum"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G System",
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Enzyme Immunoassay (CLEIA)",
        "Automated quantitative assay",
        "Two-step sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Immunoreaction Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Lumipulse G B\u2022R\u2022A\u2022H\u2022M\u2022S PCT chemiluminescent immunoassay and calibrator set for quantitative measurement of procalcitonin to aid in assessment of sepsis risk and antibiotic therapy decision-making.",
    "Indications for Use Summary": "Aids in risk assessment of critically ill ICU patients for progression to severe sepsis/septic shock, assessment of 28-day mortality risk in sepsis/septic shock, and decision making on antibiotic therapy or discontinuation for suspected or confirmed sepsis or lower respiratory tract infections, using procalcitonin levels in serum and plasma on the LUMIPULSE G System.",
    "fda_folder": "Microbiology"
}